Open Nav

Please submit your session questions in advance at


  • Zandy Forbes, MeiraGTx

MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with five programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Though initially focusing on the eye, salivary gland and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

  • Date:Monday, February 11
  • Time:10:00 AM - 10:15 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance:

    Click here.

  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:22855
  • Goal for Presentation:Exposure to potential partners, investors, advocacy groups
  • Company
  • Company HQ City:New York
  • Company HQ State:New York
  • Company HQ Country:United States
  • Market Cap:Approx 370 Million (as of 10/16)
  • Ticker:MGTX
  • Exchange:Nasdaq
  • CEO/Top Company Official:Alexandria 'Zandy' Forbes
  • Year Founded:2015
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development:4 Ph 1/2 trials ongoing, 3 ocular (ACHM, XLRP, RPE65), 1 Xerostomia
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):4-6 programs (ocular & Neurodegenerative)
  • Additional Information/Comments:2018 has been a year of exciting activity for MeiraGTx. In addition to supporting four ongoing clinical trials, the company also made numerous regulatory and business development advances. In the first half of the year, MeiraGTx received several designations from both U.S. and EU regulatory agencies for the its ocular indications, it’s most advanced program within its gene therapy platform. More recently, MeiraGTx proudly announced the acquisition of a Phase 2 Parkinson’s disease gene therapy candidate. Furthermore, MeiraGTx also announced developments for its manufacturing, completing a 29,000-square foot cGMP manufacturing facility in London, and for its proprietary gene regulation technology. In October, MeiraGTx signed a scientific collaboration with J&J Innovation to advance the company’s Riboswitch technology, a gene regulation platform that incorporates an on/off switch for gene expression into the gene therapy vector which can then be activated using a small molecule.
Zandy Forbes